Ignacio
Melero Bermejo
Catedrático de Universidad
Hospital General Universitario Gregorio Marañón
Madrid, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital General Universitario Gregorio Marañón (9)
2024
-
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548
2023
-
Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control
Journal for immunotherapy of cancer, Vol. 11, Núm. 1
2021
-
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
Journal of Hepatology, Vol. 75, Núm. 3, pp. 600-609
2020
-
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial
JAMA Oncology
-
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors
Science Translational Medicine, Vol. 12, Núm. 565
2019
-
For whom the cell tolls? Intratumoral treatment links innate and adaptive immunity
Clinical Cancer Research, Vol. 25, Núm. 4, pp. 1127-1129
-
Immunotherapeutic effects of intratumoral nanoplexed poly I:C
Journal for ImmunoTherapy of Cancer, Vol. 7, Núm. 1
-
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Nature, Vol. 569, Núm. 7756, pp. 428-432